Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 275

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 2
Chunk 275
---
 for accounting, audit, legal and consulting services, as well as costs associated with
maintaining compliance with Nasdaq listing rules and SEC requirements, director and officer liability insurance, investor and public
relations activities and other expenses associated with operating as a public company.

Other
Income (Expense), Net

Other
income (expense), net consists predominantly of interest income from interest bearing bank accounts, interest expense on payables, gains
recorded on settlements reached with vendors on payables, and the gain or loss on the revaluation of earnout and derivative liabilities,
which represents the change in fair value of earnout liabilities or outstanding warrants between periods.

Results
of Operations for the Three Months Ended June 30, 2025 and 2024

    For the Three Months Ended  June 30,  

    2025 (Successor)  
    2024 (Successor)  
    Difference  
    Percentage Change 
  
    Operating expenses: 

    Research and development 
    $2,753,963  
    $2,714,344  
    $39,619  
     1.5%
  
    General and administrative 
     1,969,828  
     2,433,893  
     (464,065) 
     (19.1)%
  
    Total operating expenses 
     4,723,791  
     5,148,237  
     (424,446) 
     8.2%
  
    Loss from operations 
     (4,723,791) 
     (5,148,237) 
     (424,446) 
     8.2%

    Other income (expense): 

    Gain from settlement of liabilities with vendor 
     -  
     447,335  
     (447,335) 
     (100.0)%
  
    Other expenses 
     -  
     (630,775) 
     630,775  
     100.0%
  
    Change in fair value of derivative liabilities and earnout liabilities 
     -  
     2,900,000  
     (2,900,000) 
     (100.0)%
  
    Stock-based inducement expense 
     (707,300) 
     -  
     (707,300) 
     (100.0)